

Appendix 30 - MANTLE CELL LYMPHOMA

Rituximab, Dexamethasone, Cytarabine, Platinum agent	Approved settings/ treatment line	Protocols	Drugs in abbreviation	Evidence level
Alternating RCHOP/ RDHAP. Rituximab, Category 2A, Preferred Cyclophosphamide, cyctarabine, filgrastim, MESNA			Dexamethasone, Cytarabine, Platinum	Category 2A, Preferred
Cyclophosphamide, Doxorubicin, Prednisone, Cytarabine, Cisplatini, Dexamethasone		NORDIC Regimen.	vincristine, cyclophosphamide, cytarabine, filgrastim,	Category 2A, Preferred
Vincristine, doxorubicin, dexamethasone, filgrastim, methotrexate, calcium leucovorin, cytarabine, MESNA		Alternating RCHOP/ RDHAP.	Cyclophosphamide, Doxorubicin, Prednisone, Cytarabine, Cisplatin,	Category 2A, Preferred
Maintenance after aggressive therapy ST Line less aggressive therapy Bendamustine + Rituximab Category 2A, Preferred		Hyper-CVAD	vincristine, doxorubicin, dexamethasone, filgrastim, methotrexate, calcium leucovorin,	Category 2A, Preferred
aggressive therapy 1ST Line less aggressive Lenalidomide + Rituximab Lenalidomide + Rituximab Lenalidomide + Rituximab VR-CAP Cyclophosphamide, doxorubicin, prednisone, bortezomib RCHOP Rituximab, cyclophosphamide, Doxorubicin, Prednisone Doxorubicin, Prednisone Category 2A, Preferred Cotal Category 2A Category 2A Category 2A Category 2A Maintenance after less aggressive therapy Rituximab		Bendamustine + Rituximab.		Category 2B
Lenalidomide + Rituximab VR-CAP Cyclophosphamide, doxorubicin, prednisone, bortezomib RCHOP Rituximab, cyclophosphamide, cyclophosphamide, cyclophosphamide, Doxorubicin, Prednisone Modified Rituximab + Hyper- CVAD Modified Rituximab + Hyper- cyclophosphamide, vincristine, doxorubicin, dexamethasone, filgrastim, methotrexate, calcium leucovorin, cytarabine, MESNA RBAC500 Regimen Rituximab Rituximab Rituximab Rituximab Rituximab Rituximab Rituximab Amaintenance after less aggressive therapy Rituximab Lotategory 2A, Preferred Category 2A Category 2A Category 2A Category 2A Category 1, used after RCHOP or for 2-5 years after Modified rituximab+ Hyper CVAD Category 2A, Preferred Category 2A Category 2A Category 2A Category 2A, Preferred Category 2A, Preferred Category 2A, Preferred Category 2A, Preferred	aggressive therapy	Rituximab Single agent for 3 years		Category 1
VR-CAP VR-CAP Cyclophosphamide, doxorubicin, prednisone, bortezomib RCHOP Rituximab, cyclophosphamide, Doxorubicin, Prednisone Modified Rituximab + Hyper- CVAD Modified Rituximab + Hyper- CVAD RBACSO0 Regimen RBACSO0 Regimen Rituximab	1 ST Line less aggressive			
RCHOP Rituximab, cyclophosphamide, Doxorubicin, Prednisone Category 2A, Preferred Posorubicin, Prednisone Category 2A, Preferred Posorubicin, Prednisone Category 2A, Preferred Posorubicin, Prednisone Category 2A Posorubicin, Prednisone Category 2A Posorubicin, dexamethasone, filgrastim, methotrexate, calcium leucovorin, cytarabine, MESNA RBAC500 Regimen Category 2A Category 2A Maintenance after less aggressive therapy Rituximab Category 1, used after RCHOP or for 2-5 years after Modified rituximab + Hyper CVAD Posorubicin, dexamethasone, filgrastim, methotrexate, calcium leucovorin, cytarabine, MESNA Category 2A Posorubicin, dexamethasone, filgrastim, methotrexate, calcium leucovorin, cytarabine, MESNA Category 2A Posorubicin, dexamethasone, filgrastim, methotrexate, calcium leucovorin, cytarabine, MESNA Category 2A Posorubicin, dexamethasone, filgrastim, methotrexate, calcium leucovorin, cytarabine, MESNA Category 2A Posorubicin, dexamethasone, filgrastim, methotrexate, calcium leucovorin, cytarabine, MESNA Posorubicin, dexamethasone, filgrastim, methotrexate, calcium leucovorin, cytarabine, method leucovorin, cytarabine, method leucovorin, cytarabine, method leucovorin, cytarabine, method leucovorin, cytarabine, m		Lenalidomide + Rituximab		
Cyclophosphamide, Doxorubicin, Prednisone Modified Rituximab + Hyper- CVAD CVAD RBAC500 Regimen Rituximab		VR-CAP	doxorubicin, prednisone,	Category 2A, Preferred
CVAD vincristine, doxorubicin, dexamethasone, filgrastim, methotrexate, calcium leucovorin, cytarabine, MESNA RBAC500 Regimen Rituximab Rituximab Category 2A Category 1, used after RCHOP or for 2-5 years after Modified rituximab+ Hyper CVAD 2nd line, Short response Ibrutinib ± Rituximab Category 2A, preferred		RCHOP	cyclophosphamide,	Category 2A, Preferred
Maintenance after less aggressive therapy Rituximab Category 1, used after RCHOP or for 2-5 years after Modified rituximab+ Hyper CVAD 2nd line, Short response Ibrutinib ± Rituximab Category 2A, preferred		7.	vincristine, doxorubicin, dexamethasone, filgrastim, methotrexate, calcium leucovorin,	Category 2A
aggressive therapy RCHOP or for 2-5 years after Modified rituximab+ Hyper CVAD 2nd line, Short response Ibrutinib ± Rituximab Category 2A, preferred		RBAC500 Regimen		Category 2A
2 nd line, Short response Ibrutinib ± Rituximab Category 2A, preferred		Rituximab		RCHOP or for 2-5 years after Modified rituximab+
	·	Ibrutinib ± Rituximab		
				Category 2A, preferred



Approved settings/ treatment line	Protocols	Drugs in abbreviation	Evidence level
2 nd line, Partial response to prior therapy	Bendamustine ± Rituximab		Category 2A, preferred
	Lenalidomide ± Rituximab		Category 2A, preferred
	Bortezomib ± Rituximab		Category 2A, preferred
	VR-CAP	Cyclophosphamide, doxorubicin, prednisone, bortezomib	Category 2A, preferred
	RCHOP	Rituximab, cyclophosphamide, Doxorubicin, Prednisone	Category 2A, preferred
2 nd line, Extended	Ibrutinib ± Rituximab		Category 2A, preferred
response to prior therapy	Lenalidomide ± Rituximab		Category 2A, preferred
	Bendamustine ± Rituximab		Category 2A, preferred
	Bortezomib ± Rituximab		Category 2A, preferred
	VR-CAP	Cyclophosphamide, doxorubicin, prednisone, bortezomib	Category 2B
	RCHOP	Rituximab, cyclophosphamide, Doxorubicin, Prednisone	Category 2B
	Bedamustine, Bortezomib and Rituximab		Category 2B